CP
Caligan Partners Portfolio holdings
AUM
$515M
This Quarter Return
+13.03%
1 Year Return
+70.09%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$143M
AUM Growth
+$143M
(+19%)
Cap. Flow
+$14.1M
Cap. Flow
% of AUM
9.81%
Top 10 Holdings %
Top 10 Hldgs %
99.93%
Holding
12
New
1
Increased
1
Reduced
3
Closed
1
Top Buys
| 1 |
Exelixis
EXEL
|
$16.5M |
| 2 |
Anika Therapeutics
ANIK
|
$3.55M |
Top Sells
| 1 |
ADMA Biologics
ADMA
|
$3.35M |
| 2 |
Evolus
EOLS
|
$1.84M |
| 3 |
SCTL
Societal CDMO, Inc. Common Stock
SCTL
|
$626K |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$159K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Liquidia Corp
LQDA
$2.38B
| $63.9M | 44.55% |
9,243,627
| – | – |
|
|
2
Anika Therapeutics
ANIK
$135M
| $20.5M | 14.33% |
715,291
+123,616
| +21% | +$3.55M |
|
3
Standard BioTools
LAB
$481M
| $16.7M | 11.67% |
8,576,799
| – | – |
|
|
4
Exelixis
EXEL
$10.1B
| $16.5M | 11.51% |
+850,000
| New | +$16.5M |
|
|
5
Evolus
EOLS
$494M
| $12.9M | 8.99% |
1,523,484
-217,216
| -12% | -$1.84M |
|
|
6
ADMA Biologics
ADMA
$4.12B
| $5.5M | 3.84% |
1,662,613
-1,013,480
| -38% | -$3.35M |
|
|
VRNA
7
Verona Pharma
VRNA
$9.16B
| $3.68M | 2.56% |
183,064
| – | – |
|
|
SCTL
8
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $1.28M | 0.89% |
1,077,268
-525,946
| -33% | -$626K |
|
9
EyePoint Pharmaceuticals
EYPT
$797M
| $1.28M | 0.89% |
435,298
| – | – |
|
|
ALIM
10
DELISTED
Alimera Sciences, Inc.
ALIM
| $1.01M | 0.7% |
478,777
| – | – |
|
11
Agios Pharmaceuticals
AGIO
$2.19B
| $99.5K | 0.07% |
4,333
| – | – |
|
|
12
Jazz Pharmaceuticals
JAZZ
$7.75B
| – | – |
-1,000
| Closed | -$159K |
|